Rea developed the first at-home diagnostic test that tracks biochemical markers of preterm birth (PTB). Our solution allows doctors to continuously follow up pregnant women at risk of PTB to anticipate a potential early delivery.

Today, all of the medical examinations to monitor the risk of a PTB require invasive inspections of pregnant women. These tests have to be performed by a medical professional in a hospital, limiting significantly the number of pregnant women that can be tested.

Our technology could enable obstetricians to provide personalized prophylactic treatments to decrease neonatal mortalities and morbidities.

PTB is the leading cause of death among children <5 years of age &, every year, an estimated 15 million babies are born preterm.

News

09.12.2025 IMD Startup Competition announces 2026 Winners (startupticker.ch)
02.06.2025 MassChallenge Switzerland presents 2025 cohort (startupticker.ch)
22.01.2024 DOPPL and Rea Diagnostics get FIT Funding Boost (startupticker.ch)
18.02.2020 10 Swiss Medtech Startups to Watch in 2020 (venturelab.swiss)

Milestones/News

Videos and Presentations


A Kickers' World, Episode 6 REA co-founders CEO Loulia Kassem and CTO Erick Garcia


Pitch Startup Champions Seed Night 2020

Player is loading...


Rea: The smart pad


A Kickers' World, Episode 6 REA co-founders CEO Loulia Kassem and CTO Erick Garcia


REA